Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Diabetes Care|February 24, 2001
Renal gluconeogenesis: its importance in human glucose homeostasisJ E Gerich, C Meyer, H J Woerle, et al.
Diabetes, Obesity & Metabolism|October 26, 2012
Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteersS Macha, P Rose, M Mattheus, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 26, 2011
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized studyD R Owens, R Swallow, K A Dugi, et al.
Diabetes, Obesity & Metabolism|July 5, 2016
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsA Salsali, G Kim, H J Woerle, et al.
International Journal of Clinical Practice|March 26, 2013
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 yearsB Gallwitz, J Rosenstock, A Emser, et al.
Neurogastroenterology and Motility|February 18, 2009
GLP-1 regulates gastroduodenal motility involving cholinergic pathwaysJ Schirra, M Nicolaus, H J Woerle, et al.
Diabetes, Obesity & Metabolism|March 18, 2011
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled studyR Gomis, R-M Espadero, R Jones, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairmentS Macha, M Mattheus, A Halabi, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 30, 2010
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteersE U Graefe-Mody, A Jungnik, A Ring, et al.
Diabetes, Obesity & Metabolism|February 13, 2013
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetesE Ferrannini, L Seman, E Seewaldt-Becker, et al.
Pageof 5